CVS Health lifts its outlook as Aetna recovers and plans a split

What happened

CVS Health reported third-quarter revenue of $108.4 billion on Wednesday 4 November, raised its full-year outlook and said it plans to split into two public companies by the first half of 2028. ^{[1, 2]}

Revenue was 5.4 percent higher than the $102.9 billion of a year earlier, the company reported. Operating income was $3.6 billion, against a loss of $3.2 billion a year before, when a $5.7 billion goodwill impairment, a write-down of what it paid for its care-delivery businesses, hit the results. ^{[1, 3]}

One company would keep the CVS Health name for now and hold Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health under chairman and chief executive David Joyner. The other, CVS Pharmacy, would hold about 9,000 drugstores, mail pharmacy, MinuteClinic and Health100, led by group president Prem Shah. Healthcare Dive reported that, according to Joyner, regulatory pressure is not the reason for the split. ^{[2, 5, 7]}

Why it matters

The quarter shows Aetna's insurance margins still mending: the Health Care Benefits segment's adjusted operating income was $912 million, against $314 million a year earlier. The split keeps Aetna with Caremark, the pharmacy benefit manager, and Insurance Business noted that it leaves the insurer-owned benefit manager, the model that draws regulatory scrutiny, intact. ^{[1, 6]}

The three businesses

Aetna paid out 91.3 percent of its premiums in medical costs in the quarter, down from 92.8 percent, a measure the company calls the medical benefit ratio. CVS credited better results in its government business. Medical membership was 26.1 million, about 600,000 fewer than a year earlier, after Aetna left the individual exchange market in 2026, the 10-Q said. ^{[1, 3, 6]}

Health Services, home of Caremark, had revenue of $54.0 billion, up 9.5 percent, which the company put down to the mix of drugs and price increases on brand-name medicines. Its adjusted operating income was $2.1 billion, up 2.7 percent. ^[1]

Pharmacy and Consumer Wellness, the drugstores, had revenue of $35.5 billion, down 2.0 percent, on regulated price cuts for some drugs, new generics and lower reimbursement, the company said. Its adjusted operating income was up 10.6 percent to $1.6 billion, helped by pharmacy assets bought from Rite Aid in 2025. ^[1]

The outlook

CVS now expects full-year revenue of at least $420.0 billion, against at least $414.0 billion in its August release. It raised its forecast of cash flow from operations to at least $15.5 billion from at least $11.5 billion, and raised its per-share guidance too. ^{[1, 4]}

The company said it keeps 'a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.' Its quarterly report said use of medical care 'persisted at elevated levels in the third quarter of 2026.' ^{[1, 3]}

What settles it next

The separation still needs final approval by the board, an effective Form 10 registration statement filed with the Securities and Exchange Commission and confirmation that it is tax-free, the company said. Other leaders and board members of the two companies are to be named later. ^[2]

Who it reaches

CVS Health (CVS) is direct: the results, the raised outlook and the planned separation are all in its own filings of Wednesday 4 November. Healthcare Dive reported that the plan unwinds part of the $78 billion merger that combined CVS with Aetna. ^{[1, 2, 3, 5]}